Supernus Pharmaceuticals Inc SUPN

NAS: SUPN | ISIN: US8684591089 2/01/2026

49,47 USD (-0,46%)

(-0,46%) 2/01/2026

Grafiek Supernus Pharmaceuticals Inc

Grafiek Supernus Pharmaceuticals Inc

1 dag1d -0,46%
1 week1w -3,47%
1 maand1m 8,30%
3 maanden3m 2,40%
6 maanden6m 57,30%
1 jaar1j 33,52%
5 jaar5j 91,08%

Supernus Pharmaceuticals Inc in het nieuws

Toon enkel gratis nieuws

16 juni 2025 · ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc. · Persbericht

7 mei 2024 · M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America · Persbericht

2 mei 2022 · Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults · Persbericht

26 februari 2021 · Supernus to Present at Cowen Healthcare Conference · Persbericht

8 februari 2021 · Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients · Persbericht

6 januari 2021 · Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference · Persbericht

Profiel Supernus Pharmaceuticals Inc

Fabricage van farmaceutische preparaten

Farmaceutische producten: Andere

Gezondheidstechnologie

Website: www.supernus.com

Hoofdzetel: Rockville, Maryland Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe